Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your PatientsThe Motley Fool • 07/29/26
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 07/28/26
Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest BuySeeking Alpha • 07/27/26
Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On ThatSeeking Alpha • 07/26/26
Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management MedicationsBusiness Wire • 07/23/26
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side24/7 Wall Street • 07/22/26
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters NowZacks Investment Research • 07/22/26